After removing the nucleos(t)ide analog reverse-transcriptase inhibitor monophosphate, the mode of DNA polymerization becomes active again (bottom). The P site and N site of HIV-1 reverse ...

Specific subtypes and transmission clusters for HIV could require targeted interventions to control spread of HIV that is ...

Kidney transplantation from donors with human immunodeficiency virus (HIV) to recipients with HIV is an emerging practice. It has been performed since 2016 under the U.S. congressional HIV Organ ...

Australia: A recent study published in Clinical Infectious Diseases has shown that the current use of integrase strand ...

10月30日晚间，艾迪药业(688488.SH)发布2024年三季报。前三季度，公司实现营业收入约2.99亿元，第三季度实现营收1.18亿元，同比大增87.54%。其中，公司HIV新药销售增长喜人，有力支撑了公司的业绩增长。 报告显示，公司HIV新药第三季度销售收入约5248.59万元，同比增长284.23%，前三季度实现销售收入约1.34亿元，同比增长188.51%。 公司艾滋病领域创新药复邦德 ...

No writing assistance was utilized in the production of this manuscript. Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting ...

has approved two new HIV-1 medicines: Delstrigo and Pifeltro. The FDA has approved Pifeltro (doravirine), a new non-nucleoside reverse transcriptase inhibitor (NNRTI), as well as Delstrigo ...

其中在HIV新药方面，2024年前三季度公司HIV新药合计实现销售收入13,411.98万元，同比增长188.51%。而得益于报告期内公司扎实推进“医学引领、市场拉动、销售落地”的营销思路落地的缘故，公司第三季度HIV新药合计实现销售收入5,248.59万元，同比增长284.23%。

Gilead Sciences and MSD are advancing their once-weekly HIV treatment regimen to Phase ... an experimental nucleoside reverse transcriptase inhibitor, with Gilead’s lenacapavir, marketed as ...

This valuable study uses robust time-dependent microscopy assays to show that during HIV-1 infection, the viral accessory protein Vif causes cell cycle arrest during metaphase and not G2/M as ...

Doctors and front-line workers are watching closely as HIV rates increase significantly in Alberta. An annual Alberta Health report reveals the number of new HIV cases jumped by 73 per cent last ...